Objectives: We aimed to determine the consistency of quantitative PET measurements of metabolic tumor volume (MTV) and intratumoral heterogeneity index for primary untreated pancreatic adenocarcinomas, when using dual-time point 18 F-FDG PET/CT imaging. Methods: This is an institutional review board-approved, retrospective study including 71 patients with pancreatic adenocarcinoma, who underwent dual-time point 18 F-FDG PET/CT imaging, at approximately 1 hour (early) and 2 hours (delayed), after injection. Automated gradientbased and 50% SUV max -threshold segmentation methods were used to assess the primary tumor MTV and metabolic intratumoral heterogeneity index, calculated as the area under cumulative SUV-volume histograms (AUC-CSH), with lower AUC-CHS indexes corresponding to higher degrees of tumor heterogeneity. We defined that more than a ±10% change in MTV or AUC-CSH, compared with baseline, as clinically significant. Results: Seventy-one FDG-avid pancreatic tumors were identified, with an average tumor diameter of 3.4 ± 0.9 cm (range, 1.5-6.4 cm). Metabolic tumor volume values remained consistent between early and delayed imaging when using the gradient PET segmentation method (P = 0.086), whereas statistically significant change was seen when using 50% SUV max -threshold segmentation (P < 0.001). A decrease in more than 10% change in MTV (% ΔMTV) was observed in 70.4% (50/71) tumors, and 7.0% (5/71) of the tumors showed an increase more than 10 % ΔMTV, when using the 50% SUV max -threshold segmentation. AUC-CSH indexes showed statistically significant differences between early and delayed time points (P < 0.001), when using the gradient segmentation. AUC-CSH index decreased by 10% or greater in 40.8% (29/71) of the tumors. AUC-CSH index remained stable between early and delayed when using the 50% SUV max -threshold segmentation (P = 0.148) with percentage of change of less than 10% for all tumors. Conclusions: Metabolic tumor volume was relatively stable between early and delayed time points when PET gradient segmentation was used but changed greater than 10% in 77.4% of the tumors at delayed time point when threshold segmentation was used. The tumor heterogeneity index (AUC-CSH) changed greater than 10% in 40.8% of tumors at delayed imaging, when gradient segmentation was used but remained stable when threshold segmentation was used. It is important to standardize uptake time and segmentation methods to use FDG PET MTV and heterogeneity index as imaging biomarkers.
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18 F-FDG-PET/CT, dual time point, metabolic tumor volume, intratumoral heterogeneity, pancreatic adenocarcinoma (Clin Nucl Med 2017;42: e16-e21) P ancreatic cancer is well known for being the 5 most lethal malignancies in the world, with more than 330,000 deaths worldwide. 1 In developed countries, its annual mortality rate closely equals its incidence at 8.3 versus 8.6 per 100,000, respectively, thereby reflecting a short survival time, generally less than 1 year. 1 Pancreatic cancer is already advanced at the time of diagnosis in the majority of cases, and only 10% to 20% of patients will be considered for curative surgery, 2,3 whereas more than 50% of patients will present with metastatic disease and could only be treated with palliative chemotherapy. 4 Among the patients who undergo surgical resection, the 5-year survival rate is approximately 15% to 40%. 5, 6 As a standard of care, patients with suspected pancreatic lesions are scanned with 18 F-FDG PET/CT at 1 hour postinjection; however, it is unclear if this particular timing allows for optimal imaging of pancreatic cancer. 18 F-FDG uptake continues to rise over time in malignant tumors, even after several hours postinjection, although this is rare for benign lesions. 7, 8 At the same time, a longer distribution time allows for improvement of blood pool and urinary tract clearance of FDG and lowers background activity. Therefore, delayed scanning, in addition to the usual standard 1 hour postinjection scan, may provide additional valuable information for tumor staging and patient prognosis. 9 Dual-time point FDG-PET has been shown to differentiate between malignant and benign processes of several malignant tumors, 10 increasing the diagnostic sensitivity and specificity for head and neck cancers, breast cancer, and malignant lung lesions. 11 Other studies have demonstrated the value in grading tumors, such as breast cancers, 12 and gliomas 13 using dual-time point imaging.
The most widely used PET-derived parameter to measure tracer accumulation in PET is the maximum standardized uptake value (SUV max ), which quantifies tumor glucose metabolic uptake. 14, 15 Recently, studies have supported the use of volumetric parameters such as metabolic tumor volume (MTV) as a potential marker for predicting outcome and for radiation therapy planning in patients with resectable pancreatic cancer. [16] [17] [18] [19] Furthermore, recent interest has raised in the development of new imaging strategies to assess for intratumoral heterogeneity. 20, 21 To adopt new PET metrics into the clinical practice, such as MTV and intratumor heterogeneity index, it is important to determine its reproducibility. Metabolic tumor volume has been previously shown to have low interobserver variability. 22, 23 Although the impact of dual-time point SUV measurements has been evaluated in various malignant tumors, there is little knowledge about the consistency of volumetric PET parameters or intratumoral heterogeneity when using dualtime point imaging. The consistency of intratumoral heterogeneity over time has not been previously studied, and assessing the consistency of MTV measurements over time in patients is limited. 22 Our study aimed to evaluate the consistency of both volumetric PET metrics and quantitative index of intratumoral heterogeneity in patients with newly diagnosed pancreatic adenocarcinomas using dual-time point FDG-PET imaging.
PATIENTS AND METHODS
We conducted a retrospective study including 71 patients (mean age, 67 ± 9 years; range, 48-88 years), with biopsy-proven newly diagnosed pancreatic adenocarcinoma, who underwent a baseline 18 F-FDG PET/CT staging using dual-time point imaging at 1 and 2 hours after intravenous FDG injection. This was an institutional review board-approved, HIPAA-compliant, PET/CT imaging study, and patients' informed consents were waived. None of the patients had surgery, radiation therapy, or systemic chemotherapy before being scanned with 18 F-FDG PET/CT. Patients with uncontrolled diabetes, active inflammation, or second primary malignancy were excluded. The demographic patients' characteristics are detailed in Table 1 .
PET/CT Protocol
Patients were instructed to fast for at least 4 hours before scanning, and their weight, height, and blood glucose levels were recorded at the time of the scan. The mean blood glucose level was 113. Patients were scanned using a 64-MDCT lutetium oxyorthosilicate crystal scanner (Discovery VCT; General Electric Medical Systems, Waukesha, WI), in 3D acquisition mode with 4.15 minutes per bed position. The images were reconstructed using the ordered subset expectation maximization algorithm, with 128 Â 128 matrix, 2 iterations, 21 subsets, 3-mm postreconstruction Gaussian filter, standard Z filter, 4.7-mm pixel, and 3.27-mm slice thickness. PET data were reconstructed with and without CT-based attenuation using an unenhanced CT for attenuation correction and anatomical coregistration. CT parameters were 50 cm axial dynamic FOV, weight-based, 20 to 200 mA, 120 to 140 kVp, 3.75-mm slice thickness, pitch of 0.984, 0.5-second gantry rotation speed, and 512 Â 512 matrix. 24 
Image Analysis
An experienced nuclear medicine physician reviewed the PET/CT images using a MIM workstation (MIM Software, version 5.2). Axial, coronal, and sagittal PET, CT, and fused PET/CT images were used for the identification of the primary pancreatic lesion. The automated semi-quantitative PET parameters included the maximum SUV (SUV max ), reflecting a maximum single-pixel uptake value adjusted for lean body mass, the peak SUV (SUV peak ) calculated using an automated computed maximal average SUV in a 1.0 cm 3 spherical volume within the tumor, 25 the MTV expressed as tumor volume with FDG uptake, and the tumor glycolytic activity (TLG) representing the tumor metabolic volume multiplied by average SUVs of included voxels. 26 For each lesion, SUV max , SUV mean , and SUV peak , MTV and TLG were measured using 2 validated PET segmentation methods: a gradient-based and a 50% SUV max threshold.
The gradient-based segmentation was performed using an edge-detection tool that generated an automated volume of interest >VOI) within the lesion, outlined in axial, transverse, and sagittal views by placing the cursor in the center of the lesion and dragging it out until the 3 orthogonal guiding lines reached the boundaries of the FDG-avid lesion, avoiding for normal adjacent structures. For the threshold segmentation technique, a 50% SUV max threshold was applied using a spherical VOI, predefined by MIM software tool, which was placed over the lesion, adjusting to include the entire FDG-avid tumor, avoiding normal adjacent structures. Once the reader verified drawn boundaries in all 3 orthogonal planes, segmentation of the obtained volume was performed. 24 The quantitative index of intratumoral metabolic heterogeneity (AUC-CSH index) was calculated as the area under the curve (AUC) of a cumulative SUV-volume histogram (CSH) obtained by plotting the percent volume greater than the percentage of SUV max (calculated for gradient-based and for 50% SUV max threshold); with lower AUC corresponding to higher degrees of heterogeneity. 27 Early and delayed time points AUC-CSH indexes were extracted from MIM software for the 2 PET segmentation methods.
Statistical Methods
Descriptive values were expressed as the mean (±SD) or median (25th, 75th range), if data were not normally distributed. The change in the SUV max (retention index [RI]) was calculated from the 1-hour early scan and the 2-hour delayed scan according to the following formula: RI = (delayed SUV max -early SUV max )/(early SUV max ) Â 100. The relative percentages of change between early and delayed values for the other quantitative PET parameters, that is, for SUV peak , MTVand TLG, and AUC-CSH index were also calculated as follows: [(delayed (value) -early (value))/early (value)] Â 100. We defined more than ±10% of change, compared with baseline, as clinically significant. Independent Student t test was performed to compare normal variables; otherwise, nonparametric tests including 
RESULTS

Patient Characteristics
A total of 71 patients with biopsy-proven newly diagnosed pancreatic adenocarcinoma were investigated in the present study. One FDG-avid pancreatic tumor was identified in each patient. Tumor sizes, measured on the noncontrast CT, ranged from 1.5 to 6.4 cm, with a median size of 3.5 ± 0.9 cm. There were 15 patients with stage II, 34 patients with stage III, and 22 patients with stage IV pancreatic adenocarcinoma. Patients' clinical characteristics are described in Table 1 .
SUV max and SUV peak
The pancreatic tumors demonstrated increased FDG avidity at delayed time points as compared with the early time points, except for 4 cases where the tumor uptake remained stable. SUV max statistically increased from early to delayed time points (SUV max 5.6 ± 2.7 [range, 2.1-15.8] vs 7.0 ± 2.7 [range, 2.5-15.9] (paired t test, P < 0.001). An increase in SUVmax was seen in 94.4% (67/71) of the tumors with an RI of 26.8 ± 17.8% (range, 0.3%-88.5%); this increase metabolic uptake was greater than 10% in 56 tumors and greater than 20% in 41 tumors. The remainder 5.6% (4/71) of the tumors showed stability (<10% increase) in the delayed time point SUV max . Statistically significant increase was seen between early and delayed SUV peak (4.5 ± 2.1 vs 5.3 ± 2.4; P < 0.0001).
Metabolic Tumor Volume
Metabolic tumor volume measurements were found to be consistent over time when using the PET gradient segmentation method (30.8 ± 20.8 mL vs 29.5 ± 20.2 mL; P = 0.086). By contrast, when using 50% SUV max -threshold PET delineation method, average MTV values were significantly different between early and delayed scans (18.9 ± 13.0 mL vs 14.1 ± 8.8 mL) (P < 0.001, paired t test).
By using PET gradient segmentation method, MTV values remained stable between early and delayed time points for 76% of the tumors (<10% of ΔMTV); a clinically significant increase of ΔMTV was seen in 11.3% of the tumors (8/71), and a decrease in ΔMTV was observed in 12.6% (9/71) of the tumors. By using the 50% SUV max -threshold segmentation method, 70.4% of the tumors (50/71) showed a clinically significant reduction in % ΔMTV (Fig. 1) . These tumors had increase in SUV max at delayed time point. Approximately 7% tumors (5/71) showed clinically significant increase in MTV values, which had stable or slightly decrease in SUV max at delayed time point. The remainder 22.5% tumors (16/71) showed stable (±10%) MTV values at delayed time point.
Metabolic Intratumor Heterogeneity
When the gradient PET segmentation methodology was applied, statistically significant difference was seen among intratumoral heterogeneity indexes between early and delayed time points By using PET gradient segmentation method, variability in the % ΔAUC-CSH was observed over time in 43.6% (31/71) of the tumors with decreased % ΔAUC-CSH of greater than 10% in 29/71 tumors ( Fig. 2) and increased % ΔAUC-CSH of more than 10% in 2 tumors; the rest of the intratumoral heterogeneity indexes remained stable over time. We also subgrouped the tumors in 3 categories (tumors with stable MTV, with increase in MTV and with decrease in MTV over time), and no significant changes were seen between the 3 categories with regard to early (P = 0.267) or delayed AUC-CSH heterogeneity index (P = 0.996) or % change in AUC-CSH (%ΔAUC-CSH) (P = 0.051) or tumor size (P = 0.25).
By using 50% SUV max -threshold segmentation method, there was no increased or decreased clinically significant % ΔAUC-CSH over time, being the percentage of change less than 10% for all tumors. Statistically significant % ΔAUC-CSH index (P = 0.003) was seen between the 3 groups with stable MTV, increase in MTV, or decrease in MTVat delayed time point. No significant changes were seen between the 3 groups with regard to early (P = 0.199) or delayed (P = 0.15) AUC-CSH heterogeneity index or tumor size (P = 0.810).
Negative correlation was seen between AUC-CSH indexes and MTV values for either early or delayed time points (r early = −0.50, and r delayed = −0.52) using the PET gradient segmentation, meaning that tumors presenting larger metabolic volumes were more heterogeneous (ie, lower AUC-CSH indexes). There was no correlation between MTV and AUC-CSH values when using 50% SUV max -threshold PET segmentation method for either early (r = −0.09) or delayed (r = −0.2) time points.
Correlation Between the 2 Segmentation Methods
Moderate but significant correlations were found between PET gradient-based and 50% SUV max -threshold segmentation methods, for early and delayed time points, for MTV measurement (r early = 0.64 and r delayed = 0.60), and for AUC-CSH values (r early = 0.68 and r delayed = 0.58), and excellent correlation was seen FIGURE 1. PET images at early and delayed time points in axial, sagittal, and coronal projections, illustrating the pancreatic metabolic tumor volume (MTV) using gradient-based PET (in yellow) and 50% SUV max -threshold (in blue) segmentations. When using gradient segmentation, MTV remains stable between early (44.7 mL) and delayed (43.3 mL) time points, whereas MTV decreased when using 50% SUV max threshold from 24.6 to 12.1 mL.
for SUV max (r = 1) and TLG measurements (r early = 0.82 and r delayed = 0.76).
DISCUSSION
The purpose of the current study was to assess the consistency of MTV and intratumoral heterogeneity when using dualtime point 18 F-FDG PET/CT imaging in 71 newly diagnosed pancreatic adenocarcinoma tumors. Two different automated PET segmentation methods were used to compare the different PET metrics.
As expected from other publications, the FDG avidity increased over time in 94% of the pancreatic tumors. The average values of SUV max , and SUV peak were found to be significantly higher at delayed time points within the tumors (P = 0.009 and P < 0.0001, respectively). Delayed phase or dual time point after a single injection of 18 F-FDG PET/CT has been proposed for differential diagnosis of a variety of malignancies, based on the theory that 18 F-FDG uptake increases over time in malignant lesions, in contrast to stable or decreasing 18 F-FDG uptake in benign lesions. 28 Nakamoto et al investigated the role of dual-time point FDG-PET imaging in differentiating between malignant and benign pancreatic lesions, reporting that dual-time point PET scan 2 hours after FDG injection provided a higher sensitivity, specificity, and accuracy compared with those for single-time point images. 29 Metabolic tumor volume values were found to remain consistent over time when using the PET gradient segmentation method. These results are concordant with a recent publication in the setting of a different population with non-small cell lung cancer (NSCLC), where investigators found that MTV of the primary NSCLC tumor did not significantly changed between 1 and 2 hours after 18 F-FDG injection using gradient-based delineation. 22 Furthermore, we evaluated the effect of dual time point in MTV measurements using FIGURE 2. Early and delayed fused PET/CT (1) and PET (2) images in axial (A1, A2), sagittal (B1, B2), and coronal (C1, C2) projections demonstrated a large 3.6 Â 3.9 Â 4.2 cm FDG-avid pancreatic tumor within the body of the pancreas. Early images (at~1 h p.i.) shows a metabolic tumor uptake with SUV max of 9.2, metabolic tumor volume (MTV) of 56.24 mL (by gradient-based PET segmentation-in blue) and 5.8 mL (by 50% SUV max -threshold segmentation-in yellow), and a heterogeneity index (AUC-CSH) of 0.356 (by gradient based) and 0.621 (by 50% SUV max threshold). On delayed (at~2 h p.i.) images, SUV max increases to 15.6; MTV remains stable with gradient-based delineation (57.4 mL) and decreased with 50% SUV max threshold (1.7 mL). AUC-CSH indexes remained stable with 50% SUV max threshold (0.597) and decreased with gradient-based segmentation (0.291).
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Dual-Time Point and PET Segmentation another segmentation method, the 50% SUV max -threshold delineation, and we found that early and delayed average MTV values were significantly different (P < 0.001), with most of the tumors (70.4%) showing a decrease of MTVof more than 10%. This tendency of decrease of MTVover time using the threshold delineation was related to the increased of FDG avidity over time because tumors with significant smaller MTV values at delayed time points were the ones with increased in FDG avidity over time and the tumors with stable or increased in MTV values at delayed time points were the ones with stable or slightly decreased SUV max values over time.
We also compared both segmentation methods for early and delayed PET values; an excellent correlation was found between the two methods for SUV max measurements and good correlations for MTV and AUC-CSH values. These 2 methods of segmentation have been previously compared using dynamic imaging by Chen et al, concluding that tumor volumes delineated by gradient method significantly correlated with those delineated by 40% SUV maxthreshold method, in patients with head and neck cancer. 30 Hatt et al found large discrepancies in image-based determination of NSCLC tumor volumes according to the methodology used for tumor delineation. 23 Another study using a single-time point PET image found that the gradient method outperformed the threshold method in terms of accuracy and robustness. 31 Therefore, the gradient segmentation method may be more reliable for the assessment of MTV measurements over time.
In this study, we addressed the consistency of intratumoral metabolic heterogeneity indexes (AUC-CSH index) when using dual time point and different segmentation methods. By using the PET gradient segmentation, the AUC-CSH indexes were different between the 2 scans. When applying the 50% SUV max-threshold segmentation method, the heterogeneity indexes remained stable, probably related to the fact that, by using a threshold, we are only including the part of the tumor (pixels-volume) with the 50% maximum uptake, excluding areas with low FDG uptake, that is, we are considering only a smaller VOI in the tumor where the heterogeneity is not changing over time. To our knowledge, this is the first manuscript assessing the impact of dual time point together with different segmentation approaches on AUC-CSH indexes. Previously, van Velden et al 32 assessed the test-retest variability at a single time point, using various PET quantitative uptake heterogeneity measurements, including AUC-CSH, in 27 patients with colorectal carcinoma, concluding that there was a high reproducibility and reliability (intraclass correlation coefficients of 0.97) and low testretest variability (10 %) for AUC-CSH values. Hall et al 23 investigated the impact of 2 different tumor delineation methods (manual and thresholding PET) on a single-time point uptake heterogeneity, which was estimated using the coefficient of variation (COV), defined as the ratio between the standard deviation of SUV values and the mean SUV value within the MTV. Highly correlation was found between COV values for the 2 delineation methods (r = 0.98, P < 0.0001). However, COV is a simple parameter that provides a global measure of heterogeneity and may not be informative of the spatial distribution of the heterogeneity, potentially yielding the same value for very different heterogeneous distributions. 23 To date, most of the publications have focused on evaluating different metabolic heterogeneity factors using different approaches for tumor volume delineation. 33, 34 With the growing interest of texture features and tumor heterogeneity in patient's survival outcome prediction 35 and in monitoring treatment response in the future, 36 the impact of PET segmentation and scan time are important factors to be considered. Our present study has some limitations. This is a retrospective, single-center study, using 1 reader and 1 tumor type (pancreatic tumor). We used 1 single heterogeneity parameter obtained by the cumulative SUV volume histogram. 27 Furthermore, metabolic heterogeneity using 18 F-FDG PET imaging can be represented by other methods, such as textural features and elliptic solid mathematical model with homogeneous density. [37] [38] [39] It would be important to investigate the impact of uptake time on multiple heterogeneity indices.
CONCLUSIONS
The PET segmentation method and the scan time had an impact on the consistency of MTV and AUC-CSH measurements. When using dual-time point 18 F-FDG-PET/CT imaging in patients with pancreatic adenocarcinoma, MTV showed consistency between early and delayed imaging by PET gradient segmentation method, whereas 50% SUV max -threshold delineation method produced statistically significant lower MTV values at delayed time points, which corresponded to the tumors that showed increase in FDG uptake over time. AUC-CSH index changed over time when using gradient-based delineation and remained stable when using the 50% SUV max threshold, likely related to the fact that we are restricting the assessment of the tumor heterogeneity to a smaller VOI. It is important to standardize uptake time and segmentation methods when using PET MTVand heterogeneity index as imaging biomarkers for therapy response and patient outcome predictions.
